China To Fast-Track Approval For Hemophilia Drugs
This article was originally published in PharmAsia News
SHANGHAI - In an effort to combat the domestic shortage of hemophilia treatments, China's State Food and Drug Administration announced Sept. 18 that it will fast track the approval process for Bayer Healthcare's Kogenate FS (recombinant-clotting factor VIII), which has had an application pending at SFDA since last November
You may also be interested in...
BEIJING - Bayer Schering Pharma is partnering with the Chinese Society of Hematology to build a network of hemophilia treatment centers that will crisscross China, according to a Bayer executive in Asia
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).